Is Olema Pharmaceuticals (OLMA) A Bargain After Its Russell Index Additions?

Simply Wall St.

Jul 03

AdvertisementIndex additions put Olema Pharmaceuticals in front of more institutional investors Olema Pharmaceuticals (OLMA) has just been added to several Russell growth benchmarks, a change that ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2648634506"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2648634506\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2648634506?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-03 07:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648634506","market":"sg","top_or_hot":-1,"title":"Is Olema Pharmaceuticals (OLMA) A Bargain After Its Russell Index Additions?","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementIndex additions put Olema Pharmaceuticals in front of more institutional investors Olema Pharmaceuticals (OLMA) has just been added to several Russell growth benchmarks, a change that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-olema-pharmaceuticals-olma-a-bargain-after-its-russell-in\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Olema Pharmaceuticals (OLMA) A Bargain After Its Russell Index Additions?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Olema Pharmaceuticals (OLMA) A Bargain After Its Russell Index Additions?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-olema-pharmaceuticals-olma-a-bargain-after-its-russell-in><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementIndex additions put Olema Pharmaceuticals in front of more institutional investors Olema Pharmaceuticals (OLMA) has just been added to several Russell growth benchmarks, a change that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-olema-pharmaceuticals-olma-a-bargain-after-its-russell-in\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OLMA","symbol_name":"Olema Pharmaceuticals, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-olema-pharmaceuticals-olma-a-bargain-after-its-russell-in","article_id":"2648634506","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-olema-pharmaceuticals-olma-a-bargain-after-its-russell-in","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648634506","pubTimestamp":1783035587,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Index additions put Olema Pharmaceuticals in front of more institutional investors\nOlema Pharmaceuticals (OLMA) has just been added to several Russell growth benchmarks, a change that puts the stock in front of more index-tracking and institutional investors that follow these indices.\nSee our latest analysis for Olema Pharmaceuticals.\nAt a share price of $12.64, Olema Pharmaceuticals has seen short term momentum build, with a 1 month share price return of 18.24% and a 7 day move of 10.59%,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"OLMA":"Olema Pharmaceuticals, Inc.","BK4139":"生物科技","BK4505":"高瓴资本持仓","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"Olema Pharmaceuticals(OLMA)加入罗素指数后是否便宜？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OLMA":1.5,"DCF":1},"content_text":"AdvertisementIndex additions put Olema Pharmaceuticals in front of more institutional investors Olema Pharmaceuticals (OLMA) has just been added to several Russell growth benchmarks, a change that puts the stock in front of more index-tracking and institutional investors that follow these indices. See our latest analysis for Olema Pharmaceuticals. At a share price of $12.64, Olema Pharmaceuticals has seen short term momentum build, with a 1 month share price return of 18.24% and a 7 day move of 10.59%, even though the 90 day share price return is down 16.07% and the year to date share price return is down 50.00%. The 1 year total shareholder return stands at 176.59% and the 3 year total shareholder return at 39.98%, indicating a mix of recent volatility and stronger gains over a longer window that may help explain why broader index inclusion has attracted fresh attention. If the index additions have you thinking more broadly about opportunities in healthcare related growth stories, it could be worth scanning 40 healthcare AI stocks for ideas that fit a similar high research and development profile. So with Olema Pharmaceuticals trading at $12.64, carrying no reported revenue and a recent mix of sharp gains and pullbacks, is the current price leaving meaningful upside on the table or already reflecting investors’ expectations for future growth? DCF signals a wide gap between Olema Pharmaceuticals’ price and cash flow estimate On Simply Wall St’s DCF model, Olema Pharmaceuticals has an estimated future cash flow value of $212.47 per share, compared with the recent share price of $12.64. This points to a very large gap between the market price and that model output. The SWS DCF model works by projecting a company’s potential future cash flows and then discounting those back to today using an assumed required rate of return. The result is a single estimate of what those future cash flows could be worth in today’s dollars. For a clinical stage biopharmaceutical company like Olema Pharmaceuticals, this type of model leans heavily on assumptions about the timing, size and probability of future cash flows from drugs that are still in trials, because the company currently reports no revenue and a loss of $185.151m. That makes the DCF output especially sensitive to inputs around future revenue build up and margins, which can shift as trial outcomes and funding plans evolve. Look into how the SWS DCF model arrives at its fair value. Result: DCF Fair value of $212.47 (UNDERVALUED) However, Olema Pharmaceuticals still faces key risks, including clinical trial setbacks for palazestrant or OP-3136, as well as the need to fund operations while reporting no revenue and a sizeable loss. Find out about the key risks to this Olema Pharmaceuticals narrative. Another view on Olema Pharmaceuticals’ valuation While the SWS DCF model suggests a very large gap between Olema Pharmaceuticals’ estimated future cash flow value and its current $12.64 share price, a simpler check using the P/B ratio points in the same direction but with a different tone. OLMA trades at 2.3x book value versus 2.7x for the wider US biotech industry and 9.2x for peers on average, which means the stock is priced below both groups on this metric and carries a value score of 4 out of 6. This raises the question of whether investors are being cautious about its lack of revenue or overlooking its pipeline. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:OLMA P/B Ratio as at Jul 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Olema Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 42 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With Olema Pharmaceuticals showing both potential rewards and clear risks, it is worth taking a closer look at the underlying data and recent developments yourself. To see how the upside and downside stack up in one place, review the 2 key rewards and 3 important warning signs. Looking for more ideas beyond Olema Pharmaceuticals? If Olema Pharmaceuticals has sharpened your focus on where risk and reward meet, do not stop here. Broaden your watchlist with other focused stock ideas.  Target resilient income by reviewing companies in the 7 dividend fortresses that may better balance yield and stability in your portfolio. Spot potential mispricing quickly by scanning the screener containing 18 high quality undiscovered gems before they attract wider attention from other investors. Prioritise capital preservation by filtering for companies in the 75 resilient stocks with low risk scores that align with a more cautious risk profile.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}